Seminars in Oncology
Volume 31, Issue 5 , Pages 645-652 , October 2004

Diagnosis and management of oligodendroglioma

  • M.J. van den Bent

      Affiliations

    • Neuro-oncology Unit, Daniel den Hoed Cancer Clinic/Erasmus University Medical Center, Rotterdam, The Netherlands.
    • Corresponding Author InformationAddress reprint requests to Daniel ven den Bent, MD, Neuro-oncology Unit, Daniel den Hoed Cancer Clinic/Erasmus University Medical Center, PO Box 5201, 3008 AE Rotterdam, The Netherlands.

References 

  1. Cairncross G , Macdonald D , Ludwin S , et al.   Chemotherapy for anaplastic oligodendroglioma . J Clin Oncol . 1994;12:2013–2021
  2. van den Bent MJ , Kros JM , Heimans JJ , et al.   Response rate and prognostic factors of recurrent oligodendroglioma treated with PCV chemotherapy . Neurology . 1998;51:1140–1145
  3. Coons SW , Johnson PC , Scheithauer BW , et al.   Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas . Cancer . 1997;79:1381–1391
  4. Reifenberger J , Reifenberger G , Liu L , et al.   Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p . Am J Pathol . 1994;145:1175–1190
  5. Smith JS , Alderete B , Minn Y , et al.   Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype . Oncogene . 1999;18:4144–4152
  6. Cairncross JG , Ueki K , Zlatescu MC , et al.   Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas . J Natl Cancer Inst . 1998;90:1473–1479
  7. van den Bent MJ , Looijenga LHJ , Langenberg K , et al.   Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features . Cancer . 2003;97:1276–1284
  8. Yung WKA , Prados M , Yaya-Tur R , et al.   Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse . J Clin Oncol . 1999;17:2762–2771
  9. van den Bent MJ , Taphoorn MJ , Brandes AA , et al.   EORTC brain tumor group study 26971 (First line chemotherapy with temozolomide in recurrent oligodendroglioma. A phase II study) . J Clin Oncol . 2003;21:2525–2528
  10. Lee Y , van Tassel P . Intracranial oligodendrogliomas (Imaging findings in 35 untreated cases) . AJR . 1989;152:361–369
  11. Ginsberg LE , Fuller GN , Hashmi M , et al.   The significance of lack of MR contrast enhancement of supratentorial brain tumors in adults (Histopathological evaluation of a series) . Surg Neurol . 1998;49:436–440
  12. Kondziolka D , Lunsford LD , Martinez AJ . Unreliability of contemporary neurodiagnostic imaging in evaluating suspected adult supratentorial (low-grade) astrocytoma . J Neurosurg . 1993;79:533–536
  13. Reifenberger G , Kros JM , Burger P , et al.   Oligodendroglioma. Pathology and Genetics of Tumours of the Nervous System . In:  Kleihues P ,  Cavenee WK editor. World Health Organization Classification of Tumours . Lyon, France: IARC Press; 2000;p. 55–70
  14. Marie Y , Sanson M , Mokhtari K , et al.   Olig2 as a specific marker of oligodendroglial tumour cells . Lancet . 2001;358:298–300
  15. Krouwer HGJ , van Duinen SG , Kamphorst W , et al.   Oligoastrocytomas (A clinicopathological study of 52 cases) . J Neuroonncol . 1997;33:223–238
  16. Maintz D , Fiedler K , Koopmann J , et al.   Molecular genetic evidence for subtypes of oligoastrocytomas . J Neuropathol Exp Neurol . 1997;56:1098–1104
  17. Smith JS , Perry A , Borell TJ , et al.   Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytoma, and mixed oligoastrocytomas . J Clin Oncol . 2000;18:636–645
  18. Bigner SH , Matthews MR , Rasheed BKA , et al.   Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization . Am J Pathol . 1999;155:375–386
  19. Sasaki H , Zlatescu MC , Betensky RA , et al.   Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade “oligodendroglioma.” . J Neuropathol Exp Neurol . 2002;61:58–63
  20. Hoang-Xuan K , Huguet S , Mokhtari K , et al.   Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression . Neurology . 2002;57:1278–1281
  21. Mueller W , Hartmann C , Hoffmann A , et al.   Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets . Am J Pathol . 2002;161:313–319
  22. Donahue B , Scott CB , Nelson JS , et al.   Influence of an oligodendroglial component on the survival of patients with anaplastic astrocytomas (A report of Radiation Therapy Oncology Group 83–02) . Int J Radiat Oncol Biol Phys . 1997;38:911–914
  23. Pignatti F , van den Bent MJ , Curran D , et al.   Prognostic factors for survival in adult patients with cerebral low-grade glioma . J Clin Oncol . 2002;20:2076–2084
  24. Shaw EG , Scheithauer BW , O’Fallon JR , et al.   Mixed oligoastrocytomas (A survival and prognostic factor analysis) . Neurosurgery . 1994;34:577–582
  25. Winger MJ , Macdonald DR , Cairncross JG . Supratentorial anaplastic gliomas in adults . J Neurosurg . 1989;71:487–493
  26. Leighton C , Fisher B , Bauman G , et al.   Supratentorial low-grade glioma in adults (An analysis of prognostic factors and the timing of radiation) . J Clin Oncol . 1997;15:1294–1301
  27. Shaw EG , Scheithauer BW , O’Fallon JR , et al.   Oligodendrogliomas (The Mayo Clinic experience) . J Neurosurg . 1992;76:428–434
  28. Shaw EG , Scheithauer BW , O’Fallon JR . Supratentorial gliomas (A comparative study by grade and histologic type) . J Neurooncol . 1997;31:273–278
  29. Giannini C , Scheithauer BW , Weaver A , et al.   Oligodendrogliomas (Reproducibility and prognostic value of histologic diagnosis and grading) . J Neuropathol Exp Neurol . 2001;60:248–262
  30. Daumas-Duport C , Tucker ML , Kolles H , et al.   Oligodendrogliomas. Part II: A new grading system based on morphological and imaging criteria . J Neurooncol . 1997;34:61–78
  31. Kros JM , Troost D , Van Eden CG , et al.   Oligodendroglioma (A comparison of two grading systems) . Cancer . 1988;61:2251–2259
  32. Matthew J , Fuller G , Goodman JC , et al.   The impact of histology and 1p/19q status on the outcome of patients with anaplastic oligodendroglioma . Neurooncology . 2002;4:344; (abstr)
  33. Ino Y , Betensky RA , Zlatescu MC , et al.   Molecular subtypes of anaplastic oligodendroglioma (Implications for patient management at diagnosis) . Clin Cancer Res . 2001;7:839–845
  34. Bauman GS , Ino Y , Yeki K , et al.   Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendroglioma . Int J Radiat Oncol Biol Phys . 2000;48:825–830
  35. Sasaki H , Zlatescu MC , Betensky RA , et al.   PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis . Am J Pathol . 2001;159:359–367
  36. Reifenberger G , Louis DN . Oligodendroglioma (Toward molecular definitions in diagnostic neuro-oncology) . J Neuropathol Exp Neurol . 2003;62:111–126
  37. Nutt CL , Mani DR , Betensky RA , et al.   Gene expression-based classification of malignant gliomas correlates better with survival than histological classification . Cancer Res . 2003;63:1602–1607
  38. Surma-aho O , Niemelä M , Vilkki J , et al.   Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients . Neurology . 2001;56:1285–1290
  39. Reijneveld JC , Sitskoorn MM , Klein M , et al.   Cognitive status and quality of life in suspected versus proven low-grade gliomas . Neurology . 2001;56:618–623
  40. Klein M , Heimans JJ , Aaronson NK , et al.   Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low grade gliomas (A comparative study) . Lancet . 2002;360:1361–1368
  41. Barker FG , Chang CH , Huhn SL , et al.   Age and the risk of anaplasia in magnetic resonance-nonenhancing supratentorial cerebral tumors . Cancer . 1997;80:936–941
  42. Berger MS , Deliganis AV , Dobbins J , et al.   The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas . Cancer . 1994;74:1784–1791
  43. Celli P , Nofrone I , Palma L , et al.   Cerebral oligodendroglioma (Prognostic factors and life history) . Neurosurgery . 1994;35:1018–1035
  44. Schiffer D , Dutto A , Cavalla P , et al.   Prognostic factors in oligodendroglioma . Can J Neurol Sci . 1997;24:313–319
  45. Kros JM , Pieterman H , Van Eden CG , et al.   Oligodendroglioma (The Rotterdam-Dijkzigt experience) . Neurosurgery . 1994;34:959–966
  46. Walker MD , Alexander E , Hunt WE , et al.   Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial . J Neurosurg . 1978;49:333–343
  47. Karim ABMF , Afra D , Bleehen NM , et al.   Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer study 22845 with the Medical Research Council study BRO4: An interim analysis . Int J Radiat Oncol Biol Phys . 2002;52:316–324
  48. Gannett DE , Wisbeck WM , Silbergeld DL , et al.   The role of postoperative irradiation in the treatment of oligodendroglioma . Int J Radiat Oncol Biol Phys . 1994;30:567–573
  49. Wallner KE , Gonzales M , Sheline GE . Treatment of oligodendrogliomas with or without postoperative irradiation . J Neurosurg . 1988;68:684–688
  50. Bullard DE , Rawlings CE , Philllips B , et al.   Oligodendroglioma. An analysis of the value of radiation therapy . Cancer . 1987;60:2179–2188
  51. Nijjar TS , Simpson WJ , Gadalla T , et al.   Oligodendroglioma. The Princess Margaret Hospital Experience (1958–1984) . Cancer . 1993;71:4002–4006
  52. Karim ABMF , Maat B , Hatlevoll R , et al.   A randomized trial on dose-response in radiation therapy of low grade cerebral glioma (European Organization for Research and Treatment of Cancer (EORTC) study 2284) . Int J Radiat Oncol Biol Phys . 1996;36:549–556
  53. Shaw E , Arusell RM , Scheithauer B , et al.   A prospective randomized trial of low versus high dose radiation in adults with a supratentorial low grade glioma (Initial report of a NCCTG-RTOG-ECOG study) . J Clin Oncol . 2002;20:2267–2276
  54. Nutt CL , Noble M , Chambers AF , et al.   Differential expression of drug resistance genes and chemosensitivity in glial cell lineages with differential response of oligodendrogliomas and astrocytomas to chemotherapy . Cancer Res . 2000;60:4812–4818
  55. Soffietti R , Ruda R , Bradac GB , et al.   PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas . Neurosurgery . 1998;43:1066–1073
  56. Mason WP , Krol GS , DeAngelis LM . Low-grade oligodendroglioma responds to chemotherapy . Neurology . 1996;46:203–207
  57. van den Bent MJ , Keime-Guibert F , Brandes AA , et al.   Temozolomide chemotherapy in recurrent oligodendroglioma . Neurology . 2001;57:340–342
  58. van den Bent MJ , Chinot O , Boogerd W , et al.   EORTC Brain Tumor Group study 26972: Second line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV-chemotherapy. A phase II study . Ann Oncol . 2003;14:599–602
  59. Constanza A , Borgogne M , Nobile M , et al.   Temozolomide in recurrent oligodendroglioma. A phase II study . Neurooncology . 2001;3:S66; (abstr)
  60. Chinot O , Honore S , Barrie M , et al.   Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy . J Clin Oncol . 2001;19:2449–2455
  61. Peterson K , Paleologos N , Forsyth P , et al.   Salvage chemotherapy for oligodendroglioma . J Neurosurg . 1996;85:597–601
  62. Chamberlain MC , Kormanik PA . Salvage chemotherapy with paclitaxel for recurrent oligodendrogliomas . J Clin Oncol . 1997;15:3427–3432
  63. Chamberlain M . Salvage chemotherapy with CPT-11 for recurrent oligodendroglioma . J Neurooncol . 2002;59:157–163
  64. Soffietti R, Nobile M , Rudá R , et al.   Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine and vincristine) . Cancer . 2004;100:807–813
  65. Triebels V, Taphoorn MJB, Brandes AA, et al: Response to 2nd line PCV chemotherapy in recurrent oligodendroglioma after 1st line temozolomide. Neurology (in press)
  66. Cairncross JG , Swinnen LJ , Bayer R , et al.   Myeloablative chemotherapy for recurrent aggressive oligodendroglioma . Neurooncology . 2000;2:114–119
  67. Abrey LE , Childs BH , Paleologos N , et al.   High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma . J Neurooncol . 2003;65:127–134
  68. Glioma Meta-Analysis Group . Chemotherapy in adult high-grade glioma (A systematic review and meta-analysis of individual patient data from 12 randomised trials) . Lancet . 2002;359:1011–1018
  69. DeAngelis LM , Burger PC , Green SB , et al.   Adjuvant chemotherapy for malignant glioma (Who benefits?) . Ann Neurol . 1998;44:691–695
  70. Streffer J , Schabet M , Bamberg M , et al.   A role for preirradiation PCV chemotherapy for oligodendroglial brain tumors . J Neurol . 2000;247:297–302
  71. Brada M , Viviers L , Abson C , et al.   Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas . Ann Oncol . 2003;14:1715–1721
  72. Buckner JC , Gesme D , O’Fallon JR , et al.   Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma (Efficacy and and associations with chromosomal abnormalities) . J Clin Oncol . 2003;21:251–255
  73. van den Bent MJ , van der Rijt CCD , Enting RE , et al.   PCV chemotherapy in newly diagnosed and recurrent low grade oligodendroglial tumors . Neurooncology . 2002;4:378

PII: S0093-7754(04)00328-8

doi: 10.1053/j.seminoncol.2004.07.006

Seminars in Oncology
Volume 31, Issue 5 , Pages 645-652 , October 2004

Article Tools